ERNA - Company ID 0000748592
The table below shows Eterna Therapeutics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$2.26M | -$2.06M | -$3.75M | -$6.05M | -$5.43M | -$3.43M |
| Capital expenditure | $2.00K | - | $101.00K | $0.00 | $46.00K | $0.00 |
| Investing cash flow | -$2.00K | - | -$97.00K | $0.00 | -$46.00K | $267.00K |
| Dividends paid | - | - | - | - |
Eterna Therapeutics Inc. reported operating cash flow of -$7.02M for fiscal year 2025. That is up 55.7% from -$15.84M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $23.00K (FY 2016) to -$7.02M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $9.56M | $2.25M | $1.39M | $0.00 | $11.99M | $9.94M |